# Prothena Corporation plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Prothena Corporation plc). ## Overview Prothena Corp. Public Ltd Co. is an Irish-domiciled clinical-stage biotechnology company focused on protein dysregulation and misfolded-protein biology. Its pipeline includes antibody-based programs for neurodegenerative and rare amyloid diseases, with development activities spanning Parkinson’s disease, ATTR amyloidosis, Alzheimer’s disease, ALS, and related disorders. ## Products & services • Therapeutic antibody programs for neurodegenerative disease • Prasinezumab for Parkinson’s disease and synucleinopathies • Coramitug for ATTR amyloidosis with cardiomyopathy • BMS-986446 for Alzheimer’s disease and neurodegeneration • PRX019 for neurodegenerative disease targets • CYTOPE® platform for intracellular disease pathways - **Clinical-stage antibody programs** (70%) — Wholly owned and partnered therapeutic antibodies in clinical development. - **Collaboration and license revenue** (30%) — Revenue from partnered development work, milestones, and license arrangements. - Therapeutic antibody programs for neurodegenerative disease - Prasinezumab for Parkinson’s disease and synucleinopathies - Coramitug for ATTR amyloidosis with cardiomyopathy - BMS-986446 for Alzheimer’s disease and neurodegeneration - PRX019 for neurodegenerative disease targets - CYTOPE® platform for intracellular disease pathways ## Customers Prothena’s direct customers are pharmaceutical and biotechnology partners that fund or co-develop its programs, rather than end-patient buyers. Its collaboration model also depends on future healthcare payers and providers if any candidate reaches commercialization, because reimbursement and adoption would determine market access. - **Pharmaceutical partners** (primary) — Companies such as Roche, BMS, and Novo Nordisk that license programs, fund development, or share commercialization rights. - **Biotechnology collaborators** (primary) — Partners that support clinical trials, target discovery, or regional commercialization of specific assets. - **Healthcare providers** (secondary) — Neurology, cardiology, and specialty treatment centers that would prescribe approved therapies. - **Payers and reimbursement bodies** (secondary) — Public and private payers that would determine coverage and access for any approved product. - Pharma partners that license or co-develop pipeline assets - Biotech collaborators funding clinical development work - Potential future prescribers treating neurodegenerative disease - Hospitals and specialty clinics for amyloid and CNS therapies - Government and commercial payers that determine reimbursement ## Geography Prothena is headquartered in Ireland and listed on Nasdaq in the United States, while its research, development, and partner relationships are international. Its business is concentrated in global clinical development rather than manufacturing, and it relies on third-party CROs, manufacturers, and collaborators across multiple countries. - Irish-domiciled company with Nasdaq listing in the U.S. - Clinical development is managed through global partners and CROs - Manufacturing of clinical supplies is outsourced to third parties - Commercial exposure would be global if programs are approved - No country-level revenue disclosure was provided in the excerpts ## Strategy Prothena’s strategy is to advance a small number of high-science programs through clinical development and use partnerships to share cost, expertise, and commercialization reach. It also evaluates whether to self-commercialize, co-promote, license regionally, or out-license each asset depending on the program and market opportunity. - **Advance partnered and wholly owned clinical programs** (short-term) — Clinical progress is the main driver of value creation in a biotech without marketed products. - **Preserve commercialization optionality** (medium-term) — Different assets may require different launch models, from co-promotion to out-licensing. - **Focus on protein dysregulation biology** (long-term) — The company’s scientific edge comes from targeting misfolded proteins across CNS and peripheral diseases. - Advance late-stage and early-stage protein-dysregulation programs - Use partnerships to fund development and broaden expertise - Retain optionality on commercialization and regional rights - Focus internal resources on programs with the strongest biology - Partner or out-license earlier-stage assets when appropriate ## Risks Prothena faces the classic risks of a clinical-stage biotech: clinical failure, regulatory delay, and dependence on external funding and partners. Its revenue is collaboration-based and can be volatile, while future commercialization would also depend on reimbursement, manufacturing, intellectual property protection, and third-party execution. - **Clinical development failure** [critical] — Pipeline value depends on proving safety and efficacy in human trials, which is inherently uncertain. - **Dependence on collaboration partners** [high] — A large share of activity and revenue is tied to partners that control or influence development and manufacturing. - **Capital and liquidity risk** [high] — The company expects ongoing R&D spend before any product sales, so financing needs can persist. - **Intellectual property risk** [high] — Biotech value depends on patent scope, enforceability, and freedom to operate. - **Reimbursement and commercialization risk** [medium] — Even approved therapies may not gain broad access without payer coverage and adequate pricing. - Clinical trials may fail or produce inconclusive results - Revenue depends heavily on collaboration milestones and timing - The company relies on partners and CROs for development and manufacturing - Patent and exclusivity protection may be challenged or expire - Future products may face payer coverage and reimbursement pressure - Biotech funding needs can require additional capital ## Accounting Revenue recognition is a key accounting judgment because Prothena records collaboration revenue as performance obligations are satisfied, which can create large swings between periods. Deferred revenue, milestone timing, and the accounting for multi-element license and development agreements materially affect reported revenue, while R&D-heavy operations and share-based compensation shape the expense base. - **Collaboration revenue recognition** — Can shift revenue between quarters and years - **Deferred revenue** — Affects future revenue recognition visibility - **Share-based compensation** — Impacts reported R&D and G&A expense - **R&D capitalization and impairment** — Can affect asset values and loss recognition - Collaboration revenue is recognized over time as obligations are performed - License and milestone timing can create large quarter-to-quarter swings - Deferred revenue reflects remaining partner performance obligations - R&D expense and share-based compensation drive reported losses - Asset impairment and valuation judgments may matter if programs are reprioritized --- *Last updated: 2026-09-24T11:32:43.595828+00:00*